Sun Pharma Announces US Availability of UNLOXCYT (cosibelimab-ipdl)
Thursday, March 12, 2026
2 min read
Canonical SourceIndia
Summary Only
What Changed
Sun Pharma's UNLOXCYT (cosibelimab-ipdl) is now available in the US, offering a new treatment option for patients with advanced cutaneous squamous cell carcinoma.
Sigvera Intelligence
Source Trust:Discovery
Source Report
Sun Pharma announced that UNLOXCYT (cosibelimab-ipdl) is now available in the U.S. for the treatment of advanced cutaneous squamous cell carcinoma (aCSCC).
Industry Context
Healthtech & Biotech
Where this signal fits in the broader landscape.
115 industry signalsProduct Launch
Source Verification
Verified from official source
Publisher—
Publication DateMar 12, 2026
Source ClassVerified Canonical
Signal Timeline
First ReportedMar 12, 2026
IndexedMar 12, 2026
PublishedMar 12, 2026
https://sunpharma.com/wp-content/uploads/2026/01/UNLOXCYT-Commercial-Launch-Press-Release.pdf
Read Full SourceGet cross-language signal intelligence
Get curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
My Notes
Sign in to save notes on signals.
Sign In